Johnson & Johnson (JNJ) Holdings Increased by Daiwa SB Investments Ltd.
Daiwa SB Investments Ltd. boosted its position in Johnson & Johnson (NYSE:JNJ) by 2,989.7% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 72,300 shares of the company’s stock after purchasing an additional 69,960 shares during the period. Johnson & Johnson makes up about 2.1% of Daiwa SB Investments Ltd.’s investment portfolio, making the stock its 12th biggest position. Daiwa SB Investments Ltd.’s holdings in Johnson & Johnson were worth $8,773,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently added to or reduced their stakes in the business. Pennsylvania Trust Co grew its stake in Johnson & Johnson by 2.3% in the 2nd quarter. Pennsylvania Trust Co now owns 412,199 shares of the company’s stock worth $50,017,000 after acquiring an additional 9,382 shares during the period. Accurate Investment Solutions Inc. grew its stake in Johnson & Johnson by 5.0% in the 2nd quarter. Accurate Investment Solutions Inc. now owns 32,266 shares of the company’s stock worth $3,915,000 after acquiring an additional 1,529 shares during the period. Lucas Capital Management grew its stake in Johnson & Johnson by 4.1% in the 2nd quarter. Lucas Capital Management now owns 41,988 shares of the company’s stock worth $5,095,000 after acquiring an additional 1,648 shares during the period. Bremer Trust National Association grew its stake in Johnson & Johnson by 8.5% in the 2nd quarter. Bremer Trust National Association now owns 20,692 shares of the company’s stock worth $2,511,000 after acquiring an additional 1,626 shares during the period. Finally, SOL Capital Management CO grew its stake in Johnson & Johnson by 6.0% in the 2nd quarter. SOL Capital Management CO now owns 12,314 shares of the company’s stock worth $1,494,000 after acquiring an additional 697 shares during the period. 66.62% of the stock is owned by hedge funds and other institutional investors.
Shares of NYSE JNJ opened at $140.47 on Tuesday. Johnson & Johnson has a 52-week low of $118.62 and a 52-week high of $148.32. The firm has a market cap of $383.33 billion, a PE ratio of 19.24, a P/E/G ratio of 2.27 and a beta of 0.69. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.65 and a quick ratio of 1.33.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 11th. Investors of record on Tuesday, August 28th were issued a dividend of $0.90 per share. The ex-dividend date was Monday, August 27th. This represents a $3.60 annualized dividend and a dividend yield of 2.56%. Johnson & Johnson’s payout ratio is 49.32%.
JNJ has been the subject of several research reports. Wells Fargo & Co reissued an “outperform” rating and set a $160.00 price objective on shares of Johnson & Johnson in a research note on Friday, September 14th. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Saturday, July 28th. Goldman Sachs Group raised shares of Johnson & Johnson from a “sell” rating to a “neutral” rating in a research note on Thursday, July 12th. Jefferies Financial Group set a $145.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Sunday, July 15th. Finally, Credit Suisse Group set a $151.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Friday, July 13th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $142.87.
In related news, CAO Ronald A. Kapusta sold 7,899 shares of Johnson & Johnson stock in a transaction on Friday, September 7th. The shares were sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the transaction, the chief accounting officer now owns 25,725 shares in the company, valued at approximately $3,528,955.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Michael E. Sneed sold 29,000 shares of Johnson & Johnson stock in a transaction on Monday, August 27th. The shares were sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the transaction, the chief operating officer now owns 59,124 shares in the company, valued at approximately $7,969,915.20. The disclosure for this sale can be found here. Insiders own 0.22% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: Market Capitalization in the Stock Market
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.